Gilead and Kite Report Adverse Reactions in CAR T-cell Therapy Trials

Gilead Sciences Inc. and its subsidiary, Kite, have released information on the common adverse reactions experienced by patients undergoing CAR T-cell therapy in various clinical trials. In patients with large B-cell lymphoma (LBCL) participating in the ZUMA-7 trial, common side effects included fever, cytokine release syndrome (CRS), fatigue, and hypotension. Similar adverse reactions were observed in the ZUMA-1 trial, with additional symptoms such as cardiac arrhythmias. For patients with indolent non-Hodgkin lymphoma (iNHL) in the ZUMA-5 trial, common reactions included fever, CRS, and hypotension.

Kite, a leader in cell therapy, has treated more patients with CAR T-cell therapy than any other company. The company operates the largest in-house cell therapy manufacturing network globally. Gilead Sciences, headquartered in Foster City, California, has been advancing innovative medicines for over three decades, focusing on treatments for life-threatening diseases.

The LYSA/LYSARC Collaborative Group, an academic cooperative focused on lymphoma research, collaborates with Gilead and Kite to enhance clinical research and treatment strategies.

Gilead and Kite have issued forward-looking statements regarding their clinical trials and regulatory applications, cautioning that actual results may differ due to various risks and uncertainties. These statements are not guarantees of future performance, and the companies do not assume any obligation to update them.

For more information, visit Kite's website or follow them on social media.